Global

No-one can say England's Accelerated Access Review, which aims to “ensure that the UK is the fastest place in the world for the design, development and widespread adoption of medical innovations" isn't aiming high, writes Leela Barham.

Reflector outlines the current measures European countries are working or collaborating on to achieve a better understanding of pricing issues.

Adoption of joint procurement agreement signals new effort from EU to better understand drug pricing issues.

Nick Hicks looks at the challenges of devising a patient advocacy strategy amid the complex political, cultural and regulatory landscape of Russia and CIS.

The UK's National Health Services needs to rethink the ‘sticking plaster’ solution of training replacement staff, writes James Brook.

Leela Barham looks at the implications of another round of cuts due to England’s Cancer Drugs Fund in November.

France is a striking example of why Europe is still only "edging towards" a genuine universal system

Plans and policies are in place to leverage the pharma industry as an integral force in transforming Mexico from a predominantly manufacturing-based economy to one driven more by innovation.

Ed Schoonveld highlights the wait confronting lung cancer patients seeking Opdivo in the UK. Can we find room for compromise?

A non-antibiotic bactericidal treatment for humans was first proven effective in 1919. Ansis Helmanis asks why they are not commercially available in the United States.

France's bid to regain its influence reveals how far Europe is from fully achieving regulatory convergence, writes Reflector.

The volatility of nation's crisis could pose greater challenges down the line

Despite rising healthcare costs, Algeria, the second-largest pharmaceutical market in Africa, remains optimistic about its pharma sector, which is riding the momentum of recent healthcare reforms. Manufacturing challenges and a growing prevalence of chronic disease, however, offer pause to the bright scenario.

The Tufts Center for the Study of Drug Development aims to plug the knowledge gap at the lower end of China's trade business through a partnership with Shanghai’s Fudan University.

Pharmaceutical companies are currently targeting the emerging markets of China and Africa for their future expansion, with the highest investment - USD 5.32 billion - just in China alone.

There are evident challenges for pharma in the ongoing Greek crisis. But, writes Reflector, there are some less evident challenges which may, over time, prove to be more difficult for the industry to cope with.

All indications are that the July 2016 deadline for transition from Europe's eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) to the new Identification of Medicinal Products (IDMP) is not achievable. Sophie Daniels reports.

Although questions around sustainability still cloud Peru’s transition to a modern healthcare system, there is no doubt that the country’s economic resurgence in recent years is having a positive impact on Peru’s pharmaceutical infrastructure.

Despite recent challenges, the Australian market still offers a number of opportunities for pharma manufacturers.

With Ireland’s signing of a vaccine procurement agreement this month, the EU’s move toward joint action on medicine acquisition is gathering pace, writes Reflector.

With the talk shifting (again) to a Greek exit from the Eurozone, what is pharma thinking?

With the perception of Morocco as just a local healthcare market waning, the country is focused on forging partnerships with other african nations and developing its pharma industrial base and export capabilities.

While the United States and Europe still dominate, CMOs and CROs based in emerging markets continue to capture market share.

NICE's proposed Innovation Office emerges with a new name. Leela Barham reports.

Reflector looks at the revitalized European Union directive on patients’ rights in cross-border healthcare.